LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・Coherus Biosciences Inc

Coherus Biosciences Inc

Suletud

Sektor Tervishoid

1.24 -5.34

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.24

Max

1.25

Põhinäitajad
By Trading Economics
Müük	17M 92M
Aktsiakasum	-0.62
Töötajad	306

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+440.15 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. nov 2024

Turustatistika
By TradingEconomics
Turukapital	4.5M 278M
Eelmine avamishind	6.58
Eelmine sulgemishind	1.24

Uudiste sentiment

By Acuity

50%

114 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

N/A / 1.39 Toetus ja vastupanu

Coherus Biosciences Inc Graafik

Seotud uudised

22. jaan 2024, 06:44 UTC

Omandamised, ülevõtmised, äriostud

Sandoz to Acquire Cimerli Business from Coherus for $170 Million

27. okt 2023, 21:40 UTC

Suurimad hinnamuutused turgudel

Coherus BioSciences Shares Climb 12% on FDA Approval for Cancer Treatment Loqtorzi

22. jaan 2024, 06:29 UTC

Omandamised, ülevõtmised, äriostud

Sandoz to Acquire Cimerli Business from Coherus for $170M

Võrdlus sarnastega

Hinnamuutus

Coherus Biosciences Inc Prognoos

Hinnasiht

By TipRanks

440.15% tõus

12 kuu keskmine prognoos

Keskmine 7.13 USD 440.15%

Kõrge 12 USD

Madal 1.5 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Coherus Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Coherus Biosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

N/A / 1.39Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

114 / 365 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Coherus Biosciences Inc

Coherus BioSciences, Inc. is a commercial stage biotherapeutics company. The Company is focused on the biosimilar and immuno-oncology market primarily in the United States. The Company’s pipeline includes the four categories product candidates, Oncology pipeline, Immunology pipeline, Ophthalmology pipeline and Small Molecule pipeline. Oncology pipeline includes Toripalimab, an anti-PD-1 antibody; UDENYCA (pegfilgrastim-cbqv); CHS-305, a bevacizumab (Avastin) biosimilar. Immunology pipeline includes CHS-1420, an anti-TNF product candidate, as an adalimumab (Humira) biosimilar. Ophthalmology pipeline includes CHS-201, a ranibizumab (Lucentis) biosimilar. CHS-201, a ranibizumab (Lucentis) biosimilar. Small Molecule pipeline includes CHS-131, an oral, small-molecule drug candidate. CHS-131 is a once-daily oral drug candidate for non-alcoholic steatohepatitis (NASH) and other metabolic conditions.